LAS VEGAS, May 15, 2018 /PRNewswire/ --
FN Media Group Presents Microcapspeculators.com News Commentary
After attacking pharmaceutical companies and the cost of medicines for more than a year, President Donald Trump will release his plans to combat drug pricing on Friday.
The near-term implications for biotechnology and pharmaceutical stocks remain murky on Wall Street. Cowen analysts said in a research note Thursday they expect Trump's speech will "be relatively benign, with more drastic proposals coming at a later date or not at all." Wells Fargo & Co.'s David Maris, meanwhile, has cautioned that calls for lower prices and greater transparency have "never been louder. Included in today's commentary is: Endonovo Therapeutics, Inc. (QTC: ENDV), Eli Lilly and Company (NYSE: LLY), ARMO BioSciences, Inc. (NASDAQ: ARMO), vTv Therapeutics, Inc. (NASDAQ: VTVT), Dynavax Technologies Corporation (NASDAQ: DVAX).
Trump's prolific tweets sank drug maker stocks in January 2017 when he accused the companies of "getting away with murder" with their pricing. Health and Human Services Secretary Alex Azar said last week that Trump's plan will be based on the 2019 budget proposal, but go "further, much further" in attacking high list prices and out-of-pocket costs. Investor fears deepened when Food and Drug Administration Commissioner Scott Gottlieb suggested the government could re-examine the safe harbor that drug rebates have under federal anti-kickback laws.
Ahead of this major announcement, the biotech sector has had some large announcements this week.
Some biotechs having major announcements this week include: Endonovo Therapeutics, Inc. (QTCQB: ENDV), Eli Lilly and Company (NYSE: LLY), ARMO BioSciences, Inc. (NASDAQ: ARMO), vTv Therapeutics, Inc. (NASDAQ: VTVT), Dynavax Technologies Corporation (NASDAQ: DVAX)
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: 13.48M, current share price: $.04
Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of Electroceutical™ Therapies, just announced a distribution agreement with Plagens Medical Consultants for the distribution of SofPulse™, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling.
SofPulse™ is the Company's FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. SofPulse™ is an easy-to-place, non-invasive device delivering targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. tMCT is an innovative process using proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and, in fact, are 1000 times lower than those emitted by a mobile phone.
The Company's Electroceutical™ Therapy has been evaluated in 5 randomized, double-blind controlled clinical trials demonstrating:
- 300% decrease in mean pain scores at 5 hours post-surgery;
- 2.2-fold reduction in narcotic use post-surgery in active users; and
- 275% lower mean IL-1 beta (inflammatory biomarker) in the wound exudates of active users following surgery
Endonovo's non-invasive pain relief therapy, SofPulse®, represents a low-cost, drug free solution to the over use of opioids following surgical procedures. Non-invasive electrotherapies, such as Endonovo's SofPulse®, are believed to modulate pain signaling through activation of peripheral endogenous opioids and opioid receptors; making these non-pharmacological devices an extremely safe and economical alternative to prescription painkillers.
Eli Lilly and Company (NYSE: LLY)
Market Cap: $81.79B, current share price: $80.17
ARMO BioSciences, Inc. (NASDAQ: ARMO)
Market Cap: $1.5B, current share price: $49.68
Eli Lilly and Company (LLY) and ARMO BioSciences, Inc. (ARMO) just announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
The acquisition will bolster Lilly's immuno-oncology program through the addition of ARMO's lead product candidate, pegilodecakin, a PEGylated IL-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. Pegilodecakin is currently being studied in a Phase 3 clinical trial in pancreatic cancer, as well as earlier-Phase trials in lung and renal cell cancer, melanoma and other solid tumor types. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development.
vTv Therapeutics, Inc. (NASDAQ: VTVT)
Market Cap: $72.70M, current share price: $2.25
vTv Therapeutics Inc. (VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company's Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer's disease, despite not meeting co-primary endpoints, identified a subpopulation that showed statistically significant benefit (unadjusted for multiple, post hoc comparisons) from azeliragon relative to placebo on ADAS-cog. The identified subpopulation consisted of participants with peak azeliragon blood plasma concentration of less than 7.5 ng/mL. Based on the subpopulation data analyses from the Part A study and the prior azeliragon trials, the company will submit a revised Statistical Analysis Plan (SAP) to the Food and Drug Administration for the Part B Study that pre-specifies a target population for the primary study analysis and expects to report Part B topline efficacy results based on 12 month data in June 2018
Dynavax Technologies Corporation (NASDAQ: DVAX)
Market Cap: $1.10B, current share price: $17.90
Dynavax Technologies Corp. (DVAX) on Tuesday reported a loss of $39 million in its first quarter. On a per-share basis, the Berkeley, California-based company said it had a loss of 63 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share. The biopharmaceutical company posted revenue of $165,000 in the period. Dynavax Technologies shares have decreased 11 percent since the beginning of the year. The stock has more than tripled in the last 12 months.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group LLC